357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results and Provides Business Update
Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
2026 Annual Meeting of Stockholders - Director Election Results
Annual Report to Security Holders
Financial Results, Press Release
Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan, Investor Presentation
Investor Presentation
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus
Definitive Revised Proxy Statement